Variability of cannabis potency in the Venice area (Italy): A survey over the period 2010-2012

Drug Testing and Analysis

Volumn 6, Issue 1-2, 2014, Pages 46-51

  Zamengo, Luca ^a   Frison, Giampietro ^a   Bettin, Chiara ^a   Sciarrone, Rocco ^a  

^a Geological and Georesources Service   (Italy)

Author keywords

Cannabis potency; CBD; CBN; Seized materials; THC; Venice (Italy)

Indexed keywords

CARDIOVASCULAR SYSTEM; POPULATION STATISTICS;

ADULT POPULATIONS; ADVERSE EFFECT; CANNABIS POTENCY; CBD; CBN; GEOGRAPHICAL AREA; SEIZED MATERIAL; STATISTICAL DATAS; TETRAHYDROCANNABINOL; VENICE (ITALY);

RESINS;

CANNABIS; PLANT RESIN; TETRAHYDROCANNABINOL;

ARTICLE; CANNABIS USE; FORENSIC TOXICOLOGY; GEOGRAPHIC AND GEOLOGICAL PARAMETERS; HEALTH SURVEY; HUMAN; ITALY; POPULATION RESEARCH; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TREND STUDY;

CANNABIS POTENCY; CBD; CBN; SEIZED MATERIALS; THC; VENICE (ITALY);

CANNABINOIDS; CANNABIS; DRONABINOL; ITALY; PLANT EXTRACTS;

EID: 84892467599     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.1515     Document Type: Article

References (24)

1. United Nations Office on Drugs and Crime (UNODC). World Drug Report, UNODC, Vienna, Austria, 2012.
2. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Annual Report: The State of the Drugs Problem in Europe, EMCDDA, Lisbon, Portugal, 2011.
3. Dipartimento Politiche Antidroga (DPA). Relazione annuale al parlamento sull'uso delle sostanze stupefacenti e sulle tossicodipendenze in Italia, DPA, Rome, Italy, 2012.
4. International Narcotics Control Board (INCB). Report of the International Narcotics Control Board for 2011, United Nations, New York, 2011.
5. N. Smith. High potency cannabis: the forgotten variable. Addiction 2005, 100, 1558.
6. D. J. Potter, P. Clark, M. B. Brown. Potency of D9-THC and Other Cannabinoids in Cannabis in England in 2005: Implications for Psychoactivity and Pharmacology. J. Forensic Sci. 2008, 53, 90.
7. C. J. A. Morgan, H. V. Curran. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br. J. Psychiatry 2008, 192, 306.
8. R. A. Sewell, M. Ranganathan, D. C. D'Souza. Cannabinoids and psychosis. Int. Rev. Psychiatry 2009, 21, 152.
9. W. Hall, L. Degenhard. Adverse health effects of non-medical cannabis use. Lancet 2009, 374, 1383.
10. J. McLaren, W. Swift, P. Dillon, S. Allsop. Cannabis potency and contamination: a review of the literature. Addiction 2008, 103, 1100.
11. F. Cascini, C. Aiello, G. Di Tanna. Increasing delta-9-tetrahydrocannabinol (D-9-THC) content in herbal cannabis over time: Systematic Review and Meta-Analysis, Curr. Drug Abuse Rev. 2012, 5, 32.
12. United Nations Office on Drugs and Crime (UNODC). World Drug Report, UNODC, Vienna, Austria, 2006.
13. S. Ross, M. ElSohly. CBN and 9-THC concentration ratio as an indicator of the age of stored marijuana samples. Bull. Narc. 1997, 49, 139.
14. I. G. Trofin, C. C. Vlad, G. Dabija, L. Filipescu. Influence of storage conditions on the chemical potency of herbal cannabis. Revista de Chimie 2011, 62, 639.
15. L. Zamengo, G. Frison, M. Gregio, G. Orrù, R. Sciarrone. Determination of illicit drugs in seized materials: Role of sampling and analysis in estimation of measurement uncertainty. Forensic Sci. Int. 2011, 208, 108.
16. L. Zamengo, C. Bettin, G. Frison, M. Gregio, R. Sciarrone. Drugs WorkBook (DWB): A tool for the analysis of illicit drugs in seized materials. Sci. Justice, 2013 (in press). Available at http://dx.doi.org/10.1016/j.scijus.2013.03.001 [15 July 2013].
17. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Table PPP-5. Potency of cannabis products at retail level, 2010, http://www.emcdda.europa.eu/stats12/ppptab5a [15 July 2013].
18. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Annual Report 2012: The State of the Drugs Problem in Europe, EMCDDA, Lisbon, Portugal, 2012.
19. E. L. Sevigny. Is today's marijuana more potent simply because it's fresher?. Drug Test. Analysis 2013, 5, 62.
20. R. G. Pertwee. Cannabinoid pharmacology: the first 66years. Br. J. Pharmacol. 2006, 147, S163.
21. J. A. Crippa, G. N. Derenusson, T. B. Ferrari, L. Wichert-Ana, F. L. Duran, R. Martin-Santos et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J. Psychopharmacol. 2011, 25, 121.
22. A. W. Zuardi. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev. Bras. Psiquiatr. 2008, 30, 271.
23. A. W. Zuardi, J. A. Crippa, J. E. Hallak, S. Bhattacharyya, Z. Atakan, R. Martin-Santos et al. A critical review of the antipsychotic effects of cannabidiol: 30years of a translational investigation. Curr. Pharm. Des. 2012, 18, 5131.
24. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). An overview of cannabis potency in Europe, EMCDDA Insights, No. 6, 2004.